Ongoing research is focused on optimizing nanoparticle physicochemical properties, surface functionalization, and multi-modal delivery systems

The gap

Evidence profile

Sourced from the future work and future-work section of the source papers, classified as general, spanning 7 journals. Those papers have been cited 12 times in total.

Supporting evidence — 8 representative gaps

• Smart Polymers in Pharmaceutical Sciences: Stimuli-Responsive Systems for Targeted Drug Release (2026) · Journal of Pharmaceutical Research and Integrated Medical Sciences · doi

  The evolution of smart polymer systems is moving rapidly from proof-of-concept lab studies to real-world biomedical applications, driven by cross-disciplinary innovation in materials science, biotechnology, and data intelligence. The next generation of smart polymers goes beyond single- trigger responses. Logic-based systems are being engineered to react to combinations of physiological signals—such as pH, temperature, enzymes, or redox gradients—allowing precise “AND/OR” gate-style control over drug release 85. This mimics the body’s own regulatory mechanisms, opening doors to more personalized and adaptive therapies. Artificial intelligence (AI) and machine learning are set to become core design tools for smart polymer development. Predictive modeling enables rapid optimization of polymer composition, crosslinking density, and stimulus-response kinetics 86. This shortens development timelines, reduces trial-and-error experimentation, and guides formulation toward clinically relevant endpoints. Smart hydrogels are transforming tissue engineering and regenerative medicine. By responding to cellular activity or microenvironmental cues, they can release growth factors and bioactive molecules in situ, creating dynamic scaffolds that support tissue growth, repair, and vascularization. 3D bioprinting technologies further enable customizable architectures for patient-specific implants 87. The focus of translational research is shifting toward long-acting injectables, implantable depots, and stimulus-sensitive devices. Early-stage human trials are already underway for smart insulin delivery systems, tumor-targeted nanocarriers, and adaptive wound dressings. Regulatory engagement, manufacturing scale-up, and robust safety profiling will be key to bridging the gap from bench to bedside 88.

  generalfuture workevidence 5/5
  Keywords: smart polymer systems intelligence release regulatory adaptive development stimulus toward tissue growth evolution moving rapidly
• Green-Synthesised Gold Nanoparticles: A Sustainable Technological Platform for Cancer Theranostics and Biomedical Innovation (2026) · Science and Technology Nexus · doi

  This review highlights the technological potential of green- synthesised AuNPs as sustainable and biocompatible platforms for cancer diagnosis and therapy. By replacing toxic chemical reductants with plant-derived biomolecules, this approach enables an eco-friendly and scalable route for producing functional nanomaterials with controlled morphology and optical properties. The ideal conditions for fabricating effective NPs are the binding behaviour, solubility, and surface modification. Such bio-capped AuNPs demonstrate strong promise in targeted drug delivery, bioimaging, and photothermal applications, offering safer and more cost-effective alternatives for cancer theranostics. However, translating these laboratory findings into clinical technologies faces key challenges. Variations in plant composition often led to inconsistent nanoparticle characteristics, affecting reproducibility and therapeutic reliability. Moreover, standardised protocols for large-scale biosynthesis, in vivo safety evaluation, and regulatory compliance are still underdeveloped. Integration of green nanofabrication with automated systems and real- time monitoring technologies remains limited, restricting scalability and commercialisation. Future advancements should focus on combining green nanotechnology with data- driven optimisation, artificial intelligence, and advanced materials engineering to achieve precise control over synthesis and performance. Developing hybrid AuNPs- based composites with biopolymers or peptides may extend applications beyond oncology into biosensing, regenerative medicine, and environmental diagnostics. Collaborative efforts linking biochemistry, nanotechnology, and clinical sciences will be critical for transforming green AuNPs into clinically approved, multifunctional therapeutic tools. Acknowledgement: MS and SK acknowledge the Senior Research Fellowship (SRF) awarded to them from the University Grants Commission (UGC). The funding agency had no role in the design, interpretation, or writing of this manuscript. Ethical approval:  Institutional Review Board approval is not required. Declaration of patient consent:  Patient's consent not required as there are no patients in this study. Financial support and sponsorship: Nil Conflicts of interest: There are no conflicts of interest.

  generalfuture workevidence 5/5
  Keywords: green aunps review cancer plant effective applications clinical technologies therapeutic nanotechnology approval required patient consent
• Nanotechnology-Driven Approaches to Bioactive Compound Delivery: Mechanisms, Platforms, and Translational Potential (2026) · BioNanoScience · doi

  The convergence of digital tools, personalized health frame- works, and scalable global solutions is reshaping the deliv- ery of bioactives based on nanotechnology. These emerging research directions represent a paradigm shift in the design, monitoring, and deployment of bioactive compounds in diverse populations and clinical contexts. 7.1 AI-Assisted NC Design Artificial intelligence (AI) is transforming NC development by replacing labour-intensive trial-and-error approaches with predictive, data-driven workflows. Traditionally, the design of nanocarriers has relied on iterative experimen- tation to identify suitable materials, encapsulation condi- tions, and release profiles a process that is time-consuming, resource-intensive, and often plagued by poor reproducibil- ity. The integration of machine learning algorithms enables researchers to analyse large datasets encompassing physi- cochemical properties, compound–carrier interactions, and biological outcomes. These algorithms learn from existing data to predict optimal pairings, such as matching hydro- phobic bioactives with lipid-based systems or selecting polymeric matrices for pH-sensitive release. Computational tools like molecular docking and modelling further acceler- ate this process by simulating bioactive–carrier interactions at the atomic level. Virtual screening of thousands of car- rier architectures allows for the prediction of binding affini- ties, encapsulation efficiencies, and release kinetics without physical synthesis, significantly reducing formulation time and material wastage. AI also supports adaptive design: real-time feedback from in vitro or in vivo assays can be incorporated to refine carrier parameters. For instance, poor cellular uptake may prompt surface modifications such as ligand attachment or charge tuning to enhance targeting. This iterative loop fosters rapid prototyping and continuous improvement [198]. Beyond laboratory optimization, AI facilitates the trans- lation of NC platforms into clinically and commercially via- ble products. Integration with wearable biosensors enables closed-loop delivery systems, where physiological biomark- ers (e.g., glucose, sweat electrolytes, cytokines) dynami- cally inform dosage and timing. This supports personalized therapy and nutrition tailored to individual health status. Advances in genomics, metabolomics, and microbiome sci- ence further enable precision dietary interventions, while scalable, low-cost production methods ensure sustainabil- ity [199]. Globally, AI-driven NC systems can be adapted to local cultural preferences, regulatory frameworks, and ingredient availability, enhancing accessibility and accept- ability. As AI tools become increasingly embedded within experimental platforms and regulatory databases, they will play a central role in streamlining NC development for tar- geted therapeutics, personalized nutrition, and equitable global deployment. 7.2 Integration of Nanocarriers with Wearable

  generalfuture workevidence 5/5
  Keywords: design tools personalized release time integration carrier systems health scalable global bioactives based deployment bioactive
• Bridging solubility, stability, and translation: advances in carbon nanotube–based drug delivery systems (2026) · DARU Journal of Pharmaceutical Sciences · doi

  Looking forward, hybrid carbon nanostructures such as nitrogen-doped carbon nanoribbons may complement CNTs platforms by enhancing drug–carrier interaction Refer- ences [113] [114] Page 19 of 24 42 strength and stability. These materials could inspire next- generation composite nanocarriers integrating multiple structural advantages. Concurrently, artificial intelligence (AI) is emerging as a transformative tool in CNTs research. Platforms such as transformer-based synthesis optimisa- tion systems enable precise control of structural parameters during chemical vapour deposition, facilitating reproduc- ible functional properties tailored for biomedical use [118]. Machine learning algorithms are increasingly employed to optimize functionalization patterns, predict toxicity profiles, and model protein corona formation. Green synthesis approaches utilizing biomass-derived carbon precursors offer environmentally sustainable pro- duction routes while potentially improving biocompatibility [119]. The integration of AI-driven design with sustainable manufacturing may accelerate the development of safer, more reproducible CNTs-based therapeutics. Ultimately, the future of CNTs nanomedicine lies in predictive design, standardized characterization, scalable production, and regulatory harmonization—factors that col- lectively determine whether laboratory innovation can tran- sition into clinical reality. [115]

  generalfuture workevidence 5/5
  Keywords: cnts carbon platforms structural based synthesis sustainable design looking forward hybrid nanostructures nitrogen doped nanoribbons
• Lipid-based nanocarriers for antifungal drug delivery (2026) · Discover Nano · cited 1× · doi

  To effectively manage the escalating global threat of fungal infections and successfully accelerate the clinical translation of advanced nanocarriers, the field must establish harmonized regulatory standards, implement robust quality-controlled manufactur- ing protocols, and prioritize early engagement with regulatory agencies [110, 143, 150]. Staniszewska et al. Discover Nano (2026) 21:298 Page 35 of 41 Furthermore, actively strengthening public and private investment partnerships is essen- tial to bridge the current translational gap. Remarkable advances in broader nanomedicine, particularly within the highly devel- oped fields of oncology and biomaterials, offer invaluable translational insights for next- generation antifungal drug delivery [125, 126, 138]. Moving forward, several highly promising technological approaches possess the potential to revolutionize this space. The development of smart nanocarriers, specifically stimuli-responsive vesicles, will allow for the active release of therapeutic payloads directly in response to specific patho- logical microenvironments [125]. Additionally, engineering advanced hybrid matrices, such as liposome-in-hydrogel systems, provides a sophisticated mechanism for the pro- longed, localized, and sustained release of complex antifungal regimens [125]. To drastically improve targeted delivery to deeper epidermal and dermal layers, future methodologies must also integrate vesicular drug delivery with advanced physi- cal permeation techniques, such as iontophoresis or sonophoresis [124]. Finally, coating ultra-deformable carriers like transethosomes with specific targeting ligands, includ- ing carbohydrates, will maximize pathogen recognition, enable diverse administration routes, and directly support emerging theranostic applications. Ultimately, sustainable financial investment and relentless translational research are the mandatory prerequi- sites required to successfully transform these highly experimental platforms into rou- tine, highly effective clinical solutions.

  generalfuture workevidence 5/5
  Keywords: highly advanced translational delivery successfully clinical nanocarriers must regulatory investment antifungal drug release directly specific
• A REVIEW ON NANOTECHNOLOGY BASED DRUG DELIVERY SYSTEM (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi

  The future prospects for drug delivery systems using nanotechnology appear to be vast as researchers are actively working towards better targeting, accuracy, safety and clinical application of these systems. Newer techniques and focus on developing smart that can be activated upon specific nanoparticles physiological temperature, stimuli enzymes, magnetic fields etc. Such smart systems deliver drugs only at target disease site, reduce tissue toxicity and increase therapeutic outcome. Apart from this, development of better targeting methods, gene therapy, mRNA therapeutics and biomimetic nanocarriers are all expected to enhance treatment options for cancer, infectious and genetic neurodegenerative diseases, disorders. The application of AI and machine learning tools may also speed up the design of more efficient and personalized nanomedicine systems. including pH, Despite great advancements, in the future challenges of scale production, safety over long term, regulatory approval and cost efficiency will need to be conquered. breakthroughs More attention will be paid to biodegradable and green nanomaterials that will also show minimal toxicity and biocompatibility. Moreover, in nanotheranostics (dual function of imaging and therapy) will further advance the real-time disease monitoring and the tailor-made pharmaceutical regulatory authorities and industry would also be vital to translate promising nanotechnology from benchtop to bed. With these challenges being successfully addressed, nanodrug delivery systems will find their prominent place in the future of personalized and sophisticated healthcare.[37] treatment options. Partnership of clinicians, scientists, CONCLUSION The application of nanotechnology based drug delivery systems have revolutionized in pharmaceutical sciences as it provides new strategies to solve various drawbacks faced by traditional drug delivery systems. With the use of nanocarriers, these systems exhibit better solubility, stability, bioavailability and therapeutic activity as well as control the delivery and targeted administration of liposomes, drugs. A lipid nanoparticles, polymeric nanoparticles, solid dendrimers and biological nanocarriers have showed promising results in improving treatment of numerous diseases. It has been proved that nanoparticles can facilitate delivery across biological barriers, shield the therapeutic molecule from degradation, and also ensure site specific delivery leading to significant advancement in the field of modern therapeutics and patient focused medicine. range of nanocarriers, like Despite this progress, the difficulties in large scale manufacturing, long term safety, stability, reproducibility and regulatory approval, still affect their clinical translation. Research are actively ongoing to engineer nanocarriers that are safer, degradable, more efficient and target specific. Various cutting-edge nanomedicine technologies are being developed such as stimuli responsive nanoparticles, theranostic platforms, gene therapy, artificial intelligence in nanomedicine design. All these technological advancement are likely to broaden the application of nanotechnology in medicine. As our scientific knowledge and technology are ever advancing, nanomedicine is considered as a promising strategy that will serve as a core pillar in precise medicine, future pharmaceuticals development. personalized therapy and REFERENCES 1. Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules, Sep. 29, 2021; 26(19): 5905. 2. Joseph TM, Kar Mahapatra D, Esmaeili A, Piszczyk Ł, Hasanin MS, Kattali M, Haponiuk J, Thomas S. Nanoparticles: Taking a Unique Position in Medicine. Nanomaterials (Basel), Jan.31; 2023; 13(3): 574. 3. Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier Drug Delivery Systems: www.wjahr.com │ Volume 10, Issue 7, 2026 │ ISO 9001:2015 Certified Journal │ 53 Vasanth et al. World Journal of Advance Healthcare Research Characterization, Limitations, Future Perspectives and Intelligence.

  generalfuture workevidence 5/5
  Keywords: systems delivery future nanoparticles drug nanocarriers nanotechnology application therapy nanomedicine medicine better safety specific therapeutic
• NANOPARTICLES AS TARGETED DRUG DELIVERY SYSTEMS: RECENT ADVANCES AND FUTURE PERSPECTIVES (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi

  Future research should focus on:  Personalized nanomedicine  Biodegradable nanocarriers  AI-assisted formulation development  Precision-targeted therapeutics  Regulatory harmonization www.wjaps.com 23 World Journal of Advance Pharmaceutical Sciences WJAPS, Volume 3, Issue 7, 2026 A the artificial

  generalfuture workevidence 5/5
  Keywords: wjaps future focus personalized nanomedicine biodegradable nanocarriers assisted formulation development precision targeted therapeutics regulatory harmonization
• Nanomaterial-Enabled Modulation of Tumor-Associated Macrophages and Dendritic Cells to Enhance Cancer Immunotherapy (2026) · Nanomaterials · cited 11× · doi

  Ongoing research is focused on optimizing nanoparticle physicochemical properties, surface functionalization, and multi-modal delivery systems - Research is needed to overcome the limitations of nanomaterial biocompatibility, targeted delivery efficiency, and potential off-target immune activation

  generalfuture-work sectionevidence 5/5
  Keywords: ongoing research focused optimizing nanoparticle physicochemical properties surface

Questions about this gap